Genmab A/S

Stocks

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 12/06/2026 pm IST			5-day change	1st Jan Change
1,619.00 ^DKK	+0.15%		+0.50%	-20.13%

11/06	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
11/06	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

Published on 05/07/2026 at 10:50 pm IST - Modified on 05/14/2026 at 06:15 pm IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Genmab First Quarter 2026 Financial Results Conference Call. As a reminder, this conference call is being recorded. During

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

11/06	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
11/06	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
10/06	Nordic stocks in North America - Autoliv rose 1.6 percent	FW
09/06	Nordic Equities in North America - AstraZeneca declines 1.8 percent	FW
08/06	Nordic stocks in North America - Ericsson fell 1.8 percent	FW
03/06	Nordic Equities in North America - Ericsson Gains 0.7 Percent	FW
02/06	U.S. Futures Slip, European Stocks Edge Up	DJ
01/06	U.S. Futures Edge Up, European Stocks Mixed	DJ
25/05	Nordic Equities in North America - Astra Zeneca Slips 0.9 Percent	FW
20/05	Nordic Equities in North America - Autoliv Gains 0.9 Percent	FW
18/05	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
12/05	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
11/05	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW
09/05	Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis
09/05	Genmab says Orbis Investment Management Limited holds 5.08% of Genmab A/S as of May 8, 2026	RE